AEON
Income statement / Annual
Last year (2024), AEON Biopharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, AEON Biopharma, Inc.'s net income was $42.01 M.
See AEON Biopharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$2.52 M |
$3.36 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1,000.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.52 M
|
$3.36 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
1
|
1
|
| Research and Development Expenses |
$14.18 M
|
$0.00
|
$34.75 M
|
$25.73 M
|
$7.32 M
|
$4.81 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.64 M
|
$0.00
|
$13.68 M
|
$11.15 M
|
$11.59 M
|
$46.04 M
|
| Other Expenses |
-$100.81 M
|
$0.00
|
$0.00
|
$10.21 M
|
-$5.61 M
|
-$10.75 M
|
| Operating Expenses |
-$72.99 M
|
$0.00
|
$48.43 M
|
$36.88 M
|
$18.91 M
|
$51.73 M
|
| Cost And Expenses |
-$72.99 M
|
$0.00
|
$48.43 M
|
$36.88 M
|
$18.91 M
|
$51.73 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$720,000.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$15,000.00
|
$7.47 M
|
| Depreciation & Amortization |
$97,000.00
|
$0.00
|
$68,000.00
|
$3,000.00
|
-$5.75 M
|
$1.26 M
|
| EBITDA |
-$27.73 M |
$0.00 |
-$48.36 M |
-$7.91 M |
-$22.14 M |
-$50.41 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
-8.79
|
-15.02
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
-6.51
|
-16.08
|
| Total Other Income/Expenses Net |
-$30.98 M
|
$0.00
|
-$4.13 M
|
$10.21 M
|
-$16.53 M
|
$199.64 M
|
| Income Before Tax |
$42.01 M
|
$0.00
|
-$52.56 M
|
-$55.64 M
|
-$32.91 M
|
$145.67 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
-13.07
|
43.39
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$28.97 M
|
$15,000.00
|
-$14.65 M
|
| Net Income |
$42.01 M
|
$0.00
|
-$52.56 M
|
-$55.64 M
|
-$32.91 M
|
$172.92 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
-13.07
|
51.51
|
| EPS |
5597.28 |
0 |
-172.03 |
-182.12 |
-1.85 |
11.69 |
| EPS Diluted |
5250.96 |
0 |
-172.03 |
-182.12 |
-1.85 |
11.69 |
| Weighted Average Shares Out |
$7,505.00
|
$516,105.00
|
$305,501.00
|
$305,501.00
|
$14.80 M
|
$14.80 M
|
| Weighted Average Shares Out Diluted |
$7,999.00
|
$516,105.00
|
$305,501.00
|
$305,501.00
|
$14.80 M
|
$14.80 M
|
| Link |
|
|
|
|
|
|
